Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Federal Trade Commission
Colorcon
Queensland Health
Deloitte
Citi
Harvard Business School
Healthtrust
Boehringer Ingelheim

Generated: August 19, 2017

DrugPatentWatch Database Preview

Sentynl Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SENTYNL THERAPS INC, and what generic alternatives to SENTYNL THERAPS INC drugs are available?

SENTYNL THERAPS INC has two approved drugs.

There are three US patents protecting SENTYNL THERAPS INC drugs.

There are ninety-three patent family members on SENTYNL THERAPS INC drugs in twenty-eight countries.

Summary for Applicant: Sentynl Theraps Inc

Patents:3
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-004Jan 7, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-005Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-003Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-001Jan 7, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-004Jan 7, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SENTYNL THERAPS INC drugs

Drugname Dosage Strength Tradename Submissiondate
fentanyl citrate
Sublingual Tablets0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg
ABSTRAL
6/19/2014

Non-Orange Book Patents for Sentynl Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,454,996Pharmaceutical composition for the treatment of acute disorders► Subscribe
8,512,747Pharmaceutical composition for the treatment of acute disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sentynl Theraps Inc Drugs

Country Document Number Estimated Expiration
Czech Republic302975► Subscribe
European Patent Office2236132► Subscribe
Spain2289829► Subscribe
Canada2820588► Subscribe
Bulgaria65502► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sentynl Theraps Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
2014000024Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
0653Netherlands► SubscribePRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Merck
Fuji
Cantor Fitzgerald
Cipla
Cerilliant
McKesson
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot